What is William Blair's Estimate for NMRA FY2029 Earnings?

Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Stock analysts at William Blair issued their FY2029 EPS estimates for shares of Neumora Therapeutics in a note issued to investors on Thursday, January 2nd. William Blair analyst M. Minter expects that the company will earn $1.47 per share for the year. The consensus estimate for Neumora Therapeutics' current full-year earnings is ($1.61) per share.

A number of other analysts have also recently commented on NMRA. HC Wainwright reiterated a "buy" rating and issued a $30.00 price target on shares of Neumora Therapeutics in a research note on Friday. Bank of America cut their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a research note on Monday. Needham & Company LLC reissued a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a research report on Thursday. Royal Bank of Canada lowered Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and dropped their price objective for the company from $29.00 to $4.00 in a research note on Thursday. Finally, JPMorgan Chase & Co. downgraded Neumora Therapeutics from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $18.00 to $15.00 in a research note on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, Neumora Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $16.50.

Neumora Therapeutics Stock Up 14.3 %

Shares of NASDAQ:NMRA traded up $0.31 during midday trading on Monday, hitting $2.48. The stock had a trading volume of 12,617,920 shares, compared to its average volume of 26,766,340. The company has a market cap of $400.67 million, a P/E ratio of -1.33 and a beta of 2.71. Neumora Therapeutics has a 12 month low of $1.83 and a 12 month high of $21.00. The business's 50-day simple moving average is $10.28 and its 200-day simple moving average is $11.46.

Neumora Therapeutics (NASDAQ:NMRA - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.06). During the same quarter in the previous year, the company posted ($1.14) earnings per share.

Insiders Place Their Bets

In other news, insider Robert A. Lenz sold 5,563 shares of Neumora Therapeutics stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $15.01, for a total transaction of $83,500.63. Following the completion of the sale, the insider now owns 322,966 shares of the company's stock, valued at approximately $4,847,719.66. This trade represents a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Matthew K. Fust sold 14,049 shares of the business's stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the completion of the sale, the director now directly owns 20,100 shares of the company's stock, valued at approximately $342,303. The trade was a 41.14 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 26.40% of the company's stock.

Institutional Investors Weigh In On Neumora Therapeutics

Large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in shares of Neumora Therapeutics by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company's stock worth $851,000 after purchasing an additional 1,629 shares during the period. Barclays PLC increased its stake in Neumora Therapeutics by 352.9% in the third quarter. Barclays PLC now owns 129,210 shares of the company's stock valued at $1,708,000 after acquiring an additional 100,678 shares during the last quarter. Geode Capital Management LLC raised its position in Neumora Therapeutics by 54.0% during the third quarter. Geode Capital Management LLC now owns 1,979,847 shares of the company's stock valued at $26,159,000 after purchasing an additional 694,385 shares in the last quarter. Wexford Capital LP lifted its stake in Neumora Therapeutics by 90.1% during the third quarter. Wexford Capital LP now owns 217,879 shares of the company's stock worth $2,878,000 after purchasing an additional 103,285 shares during the last quarter. Finally, State Street Corp lifted its stake in Neumora Therapeutics by 65.3% during the third quarter. State Street Corp now owns 1,790,707 shares of the company's stock worth $23,655,000 after purchasing an additional 707,409 shares during the last quarter. Institutional investors and hedge funds own 47.65% of the company's stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.